title: Future directions for the management of ovarian cancer.
abstract: Although the results of treatment of ovarian cancer have improved over the past 20 years with the introduction of platinum and more recently taxoid-based chemotherapy, the majority of patients still die of this disease. Further improvements may be expected by the incorporation of other new agents in more imaginative schedules, perhaps including a sequential approach or neoadjuvant regimens. Other experimental approaches that show promise include intraperitoneal treatment, e.g. genetic therapy. A better understanding of the mechanisms underlying clinical drug resistance will be important in the rational development of a number of exciting approaches aimed at overcoming this key obstacle.
authors.affiliation: CRC Department of Medical Oncology, Royal Marsden Hospital, Downs Road, Surrey SM2 5PT, Sutton, UK. stan.kaye@rmh.nthames.nhs.uk
authors.forename: S B
authors.initials: SB
authors.lastname: Kaye
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy / Q000379:methods; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005544:Forecasting; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008081:Liposomes; D010051:Ovarian Neoplasms / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D008081:Liposomes; D004317:Doxorubicin